50BA Stock Overview
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Bicycle Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.80 |
| 52 Week High | US$26.00 |
| 52 Week Low | US$11.80 |
| Beta | 0.89 |
| 1 Month Change | -4.59% |
| 3 Month Change | 35.06% |
| 1 Year Change | 16.85% |
| 3 Year Change | -16.80% |
| 5 Year Change | n/a |
| Change since IPO | -11.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| 50BA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.0% | 1.6% | -1.4% |
| 1Y | 16.9% | -21.6% | 2.2% |
Return vs Industry: 50BA exceeded the German Biotechs industry which returned -21.6% over the past year.
Return vs Market: 50BA exceeded the German Market which returned 2.2% over the past year.
Price Volatility
| 50BA volatility | |
|---|---|
| 50BA Average Weekly Movement | 19.5% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 50BA's share price has been volatile over the past 3 months.
Volatility Over Time: 50BA's weekly volatility has increased from 13% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 284 | Kevin Lee | www.bicycletherapeutics.com |
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors.
Bicycle Therapeutics plc Fundamentals Summary
| 50BA fundamental statistics | |
|---|---|
| Market cap | €937.94m |
| Earnings (TTM) | -€169.34m |
| Revenue (TTM) | €25.28m |
37.1x
P/S Ratio-5.5x
P/E RatioIs 50BA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 50BA income statement (TTM) | |
|---|---|
| Revenue | US$26.98m |
| Cost of Revenue | US$156.50m |
| Gross Profit | -US$129.52m |
| Other Expenses | US$51.14m |
| Earnings | -US$180.66m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.23 |
| Gross Margin | -480.13% |
| Net Profit Margin | -669.72% |
| Debt/Equity Ratio | 8.3% |
How did 50BA perform over the long term?
See historical performance and comparison